ERBB2 and breast carcinoma: Pooled circulating tumor DNA analysis from the MONALEESA phase III advanced breast cancer trials showed that certain genomic alterations, such as Erb-B2 receptor tyrosine kinase 2 (HER2), might be associated with favorable PFS when treated with ribociclib compared to placebo 9.